FindTrial
Sign In

Regorafenib plus nivolumab and GM-CSF in patients with advanced colorectal cancer (CRC)

Regorafenib plus nivolumab and GM-CSF in patients with advanced colorectal cancer (CRC)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038175
Enrollment
Unknown
Registered
2020-09-12
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced colorectal cancer (CRC)

Interventions

Case series:Regorafenib combined with PD-1 monoclonal antibody and GM-CSF

Sponsors

Affiliated Hospital of Xuzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Malignant solid tumors confirmed by pathology or cytology; Immunotherapy has been performed or planned for advanced colorectal cancer; screening conditions: regorafenib + PD-1/PD-L monoclonal antibody combined with GM-CSF immunotherapy.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
Efficient;—

Countries

China

Contacts

Public ContactZhengxiang Han

Affiliated Hospital of Xuzhou Medical College

394030300@qq.com+86 18052268612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026